Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 4/20 | 0.34 |
| ▸ | JAK1 | P23458 | 9/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 6/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537655 | 1.00 | PRKCA (0.35) | PRKCAPRKCIPRKCEABL1JAK1 | |
| SCHEMBL24285879 | 0.93 | JAK1 (0.36) | PRKCAPRKCIPRKCEABL1JAK1 | |
| SCHEMBL29537535 | 0.93 | JAK1 (0.36) | PRKCAPRKCIPRKCEABL1JAK1 | |
| SCHEMBL29537364 | 0.89 | CDK2 (0.34) | PRKCAPRKCIPRKCEABL1JAK1 | |
| SCHEMBL24285989 | 0.89 | CDK2 (0.34) | PRKCAPRKCIPRKCEABL1JAK1 | |
| SCHEMBL24286202 | 0.87 | ABL1 (0.44) | ABL1LRRK2 | |
| SCHEMBL29537272 | 0.83 | JAK1 (0.34) | PRKCAPRKCIPRKCEJAK1JAK2 | |
| SCHEMBL24285931 | 0.83 | JAK1 (0.34) | PRKCAPRKCIPRKCEJAK1JAK2 | |
| SCHEMBL24286074 | 0.82 | TGFBR1 (0.37) | PRKCAPRKCIPRKCERPS6KA3TGFBR1 | |
| SCHEMBL29538130 | 0.82 | TGFBR1 (0.37) | PRKCAPRKCIPRKCERPS6KA3TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214207-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1st Biotherapeutics, Inc. (KR) | 2023-07-26 | — | — | EP | claimed |
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | PRKCA 653/4885PRKCI 1554/4885PRKCE 931/4885 |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | PRKCA 653/4885PRKCI 1554/4885PRKCE 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.